Immunotherapy in Melanoma Articles | Page 3

Update Confirms Benefit of Pembrolizumab Plus Indoximod in Melanoma
Adding the IDO inhibitor indoximod to pembrolizumab (Keytruda) led to an overall response rate of 61% in patients with advanced melanoma.
Andtbacka Discusses Long-Term Data and Next Steps With T-VEC in Melanoma
Robert Andtbacka, MD, discusses the long-term results for T-VEC in melanoma and the remaining challenges with the oncolytic immunotherapy.
FDA Approves Ipilimumab for Pediatric Melanoma
The FDA has approved ipilimumab for the treatment of patients aged ≥12 years with unresectable or metastatic melanoma.
Avelumab Recommended for EU Approval for Merkel Cell Carcinoma
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of avelumab (Bavencio) for adults with metastatic Merkel cell carcinoma, according to Pfizer and Merck, the codevelopers of the PD-L1 inhibitor.
Pembrolizumab Demonstrates Long-Term OS Benefit in Advanced Melanoma
Pembrolizumab (Keytruda) provides a long-term survival benefit in both ipilimumab-naïve and ipilimumab-treated patients with advanced melanoma.
Adjuvant Nivolumab Improves RFS Versus Ipilimumab in Melanoma
Adjuvant nivolumab (Opdivo) extended recurrence-free survival compared with adjuvant ipilimumab (Yervoy) in patients with advanced melanoma enrolled in the phase III CheckMate-238 trial.
Expert Discusses IDO/PD-1 and Other Emerging Combos in Melanoma
Adil Daud, MD, discusses combination regimens and biomarkers being explored to advance immunotherapy in the field of melanoma.
Weighing Efficacy and Tolerability for Adjuvant Ipilimumab in Advanced Melanoma
Treatment with ipilimumab has been shown to improve overall survival; however, this efficacy often comes with toxicity.
Adjuvant PD-1 Inhibition on Horizon in Melanoma
Several clinical trials are examining the use of adjuvant PD-1 inhibition for patients with melanoma, with a potential new standard of care on the horizon for those at high risk of recurrence following resection.
Publication Bottom Border
Border Publication
x